Han Yu Pharmaceutical strategically invests in Carbon Cloud Intellipeptide.

On December 22, according to Han Yu Pharmaceuticals, Han Yu Pharmaceuticals officially reached a strategic investment cooperation agreement with Shenzhen Carbon Cloud Intelligent Peptide Drug Technology Co., Ltd. According to the agreement, Han Yu Pharmaceuticals will subscribe to the additional registered capital of Carbon Cloud Intelligent Peptide with 10 million yuan in cash, and after the capital increase, it will hold 0.6623% equity of Carbon Cloud Intelligent Peptide.